The pot materials will be used in PreveCeutical's soluble gel (Sol-gel) drug delivery research.
As revealed in March, the company, in a major milestone, had received the key permits to allow this material to be imported into Australia by the cannabis major.
It is being used for the group's research led by Preveceutical's chief research officer Dr Harendra Parekh at the University of Queensland.
Preveceutical aims to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders.
The advantages of Sol-gels over conventional liquid nasal sprays include reduced dosage requirements, and reduced irritation and other negative side effects.
Shares were unchanged at C$0.29.